SOLID-TIMI 52

SOLID-TIMI 52 was a randomized, double-blind, placebo-controlled trial to assess the efficacy of darapladib, a novel Lp-PLA2 inhibitor, when added to standard of care in high-risk patients stabilized after ACS.

PRESENTATIONS

TIMI 52 Slides
SOLID Ceramides (Gencer AHA 2019)

PUBLICATIONS

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome

Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome

Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial

Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials

Cystatin C Is Associated With The Risk Of Adverse Outcomes Independent Of Established And Novel Cardiorenal Markers: An Analysis From The SOLID-TIMI 52 Trial

Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial

Adverse Limb Events in Patients With Peripheral Artery Disease Presenting With Acute Coronary Syndrome: Observations From SOLID-TIMI 52

Interleukin-6 And The Risk Of Adverse Outcomes In Patients After An Acute Coronary Syndrome: Observations From The SOLID-TIMI 52 Trial

Metabolic Syndrome And The Risk Of Adverse Cardiovascular Events After An Acute Coronary Syndrome: Insights From SOLID-TIMI 52 Trial

Growth Differentiation Factor-15 (GDF-15) for Risk Stratification in Patients After an Acute Coronary Syndrome: Insights From the SOLID-TIMI 52 Trial

Performance Reports And The Utilization Of Guideline-Based Therapies In A Large Clinical Trial Population Enrolled After An Acute Coronary Syndrome: Insights From The SOLID-TIMI 52 Trial

Galectin-3 For Heart Failure Risk Stratification In Patients After Acute Coronary Syndromes (ACS): Insights From The SOLID-TIMI 52 Trial

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial

Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events

Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome